Ginkgo Bioworks Holdings, Inc. (DNA) operates in the biotechnology sector, developing cell programming platforms for therapeutics, food ingredients, and chemicals. While its core business activities are Shariah-compliant, the company fails financial screening criteria across major standards due to high debt (77.34%) and liquidity (92.00%) ratios exceeding thresholds. Non-permissible income is minimal at 0.99%, requiring purification. The stock is not included in any major Shariah indices, resulting in an overall non-compliant status. Investors should monitor debt reduction efforts and consider alternatives in the healthcare sector.